Table 2.

Evolution of thrombocytopenia subsequent to treatment with eltrombopag.

Variable	Value
Time from CAR-T infusion to PLT transfusion requirement, days	6.0 (2.0, 21.5)
Platelet count when the first dose of eltrombopag was administered, ×109/L	12.5 (9.0, 18.1)
Time from first platelet transfusion to start of eltrombopag, days	21.0 (7.5, 55.0)
Eltrombopag dose, mg/d
Initial	50 (50, 50)
Maximum	150 (50, 150)
Time on eltrombopag treatment, days	68 (48, 154)
Follow-up since the start of eltrombopag, days	122 (66, 398)
Patients who recovered counts at follow-up end and time required
Achieved platelet count ≥ 20 × 109/L, n/N (%)	29/38 (76.3)
Time from start of eltrombopag to platelet count ≥ 20 × 109/L, days	32 (14, 38)
Achieved platelet count ≥ 50 × 109/L, n/N (%)	26/38 (68.4)
Time from start of eltrombopag to platelet count ≥ 50 × 109/L, days	33 (19, 57)
Patients who did not reach counts ≥ 20 × 109/L at follow-up end
Time on treatment with eltrombopag, days	108 (63, 154)
Follow-up since the start of eltrombopag, days	108 (82, 158)

Results are median (IQR), except otherwise indicated. IQR, interquartile range.